Volume 10, Issue 3 (12-2023)
NBR 2023, 10(3): 184-193 |
Back to browse issues page
Department of Biology, Faculty of Basic Sciences, Bu-Ali Sina University, Hamadan, Iran; Department of Biology, Faculty of Basic Sciences, Afghanistan National Agriculture Science and Technology University, Kandahar, Afghanistan , s.yari@basu.ac.ir
Abstract: (664 Views)
Cisplatin (CP) is one of the most effective chemotherapeutic drugs, however, its clinical use is limited due to possesing nephrotoxicity, hepatotoxicity and hemotoxicity side effects. α-lipoic acid (ALA) is known as a powerful antioxidant with anti-inflammatory properties. The aim of this study was to evaluate the effect of ALA on cisplatin-induced hemotoxicity. In this experimental study, 35 NMRI mice were divided into five groups (7 mice/group) of Group 1 (Control), group 2 (CP), group3 (CP+ALA low dose), group 4 (CP+ALA high dose) and group 5 (ALA). ALA was administrated orally for 7 consecutive days and CP was injected intraperitoneally. At the end of the experiment, blood samples were collected and blood parameters were analyzed. Spleens belong to different groups were evaluated histologically. The data were revealed that erythrocyte count, White blood cells count and hemoglobin level were increased significantly in group2 in comparison with other groups. However, ALA administration improved CP induced changes in blood parameters. CP treatment induced histological changes such as increase in megakaryocytes count and accumulation of hemosiderin and collagen in red palp of spleen. ALA treatment improved CP induced histological alteration in groups 3 and 4. Results of the present study showed that ALA exerts protective effects on CP-induced hemotoxicity and histological alteration of spleen.
Type of Study: Original Article |
Subject:
Animal Biology
Received: 2023/01/25 | Revised: 2023/12/21 | Accepted: 2023/06/27 | Published: 2023/12/20 | ePublished: 2023/12/20
Received: 2023/01/25 | Revised: 2023/12/21 | Accepted: 2023/06/27 | Published: 2023/12/20 | ePublished: 2023/12/20
| Rights and permissions | |
 | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |